DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE
References (14)
- et al.
Lancet
(1971) - et al.
Lancet
(1971) - et al.
Gastroenterology
(1974) - et al.
Lancet
(1969) - et al.
Gastroenterology
(1978) - et al.
Gastroenterology
(1978)
There are more references available in the full text version of this article.
Cited by (294)
De-escalation of medical therapy in inflammatory bowel disease
2020, Current Opinion in PharmacologyA User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease
2020, Clinical Gastroenterology and HepatologyCitation Excerpt :O’Donoghue et al48 randomized 51 subjects with CD, treated with at least 6 months of azathioprine, to either continue or stop therapy. Relapse occurred in 5% of subjects continuing azathioprine, compared with 41% in the control group (P < .01).48 Vilien et al49 found that 85% of patients with inactive CD who continued azathioprine remained in remission, compared with 47% who stopped it (P = .043).
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
2020, The Lancet Gastroenterology and HepatologyAminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
2019, Gastroenterologia y HepatologiaAdipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2
2018, Biochemical and Biophysical Research CommunicationsEffective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine
2018, Biomedicine and Pharmacotherapy
Copyright © 1978 Published by Elsevier Ltd.